Join the club for FREE to access the whole archive and other member benefits.

Aaron Cravens

Bioengineer and CEO at Revel Pharmaceuticals

Co-founder and CEO at Revel Pharmaceuticals. Aaron is passionate to bring the anti-AGE therapeutics to the clinic. Previously, he worked at Google X and consulted for Bay Area biotech companies. He previously founded a startup in the skincare space and trained in Stanford’s IGNITE Business School Program. He has more than eight years of experience in Revel’s platform technologies of enzyme discovery and engineering.

He completed BS in Mathematics at the University of Rochester and received his PhD in Bioengineering from Stanford University.

Visit website: https://www.revelpharmaceuticals.com/team#AaronCravens

 aaron-cravens-61652162

See also: Company Revel Pharmaceuticals - Biotechnology company commercializing therapeutic enzymes to degrade age associated molecule damage.

Details last updated 22-Oct-2021

Aaron Cravens is also referenced in the following:

Engineered Enzymes to Break Extracellular Crosslinks - Aaron Cravens at Longevity Summit Dublin 2024

Aaron Cravens delivered a keynote on engineered enzymes to break extracellular crosslinks

Longevity Summit Dublin 2024

13-Jun-2024 to 16-Jun-2024

Event gathering Global Longevity and Rejuvenation community in Dublin by LEV Foundation (Dublin, Ireland)

Rejuvenation Startup Summit 2024

10-May-2024 to 11-May-2024

The leading networking event for rejuvenation startups, longevity investors and translational researchers by Forever Healthy Foundation

Aaron Cravens News

Reason reports back from Rejuvenation Startup Summit 2024

Reason reports back from Rejuvenation Startup Summit 2024

Fight Aging! - 13-May-2024

A great summary of 25 speakers who are in various stages of platform building, drug discovery and clinical trials

Reason reports back from October's Rejuvenation Startup Summit

Reason reports back from October's Rejuvenation Startup Summit

Fight Aging! - 19-Oct-2022

Some really exciting developments with quite a few in clinical trials

Revel pharmaceutics raised $8.4M to push enzyme therapies to clinic

Revel pharmaceutics raised $8.4M to push enzyme therapies to clinic

KIZOO Technology Ventures - 17-Mar-2022

Funds will be used to develop enzymes that repair collagen and reverse ageing or disease

Revel pharmaceuticals restores tissue function using AGE-cleaving enzymes

Revel pharmaceuticals restores tissue function using AGE-cleaving enzymes

Longevity Technology - 12-Oct-2021

A unique treatment approach for ageing; will soon begin trials in animals and human cadaver tissue